At a glance
ClinicalIndex Comparison Record- ✓Ambulatory status with osteoporosis diagnosis
- ✓Hip or spine BMD >2.5 SD below young healthy women average, OR >2.0 SD below with history of vertebral or nonvertebral fragility fracture
- ✕Bone diseases other than osteoporosis
- ✕Estrogen use within 3 months before enrollment or >2 months total in past year
- ✕Oral bisphosphonate use within 3 months before enrollment or >2 months total in past year
- ✕Intravenous bisphosphonate use within 12 months before enrollment
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of Nuclear Scintigraphy to Evaluate the Anabolic Effects of Teriparatide on the Skeleton in Postmenopausal Women With Osteoporosis
In Brief
A Phase 4 clinical trial evaluating teriparatide for Osteoporosis. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effects of teriparatide on skeleton images in postmenopausal women with osteoporosis. Teriparatide is a bone formation agent that stimulates the production of new bone in the skeleton. This process of bone formation can be studied using a technique commonly referred to as a bone scan or nuclear scintigraphy. This trial will test whether bone scans will identify areas of the skeleton that are forming new bone during teriparatide therapy. It also will study what these areas look like after therapy is stopped.
Study Details
Timeline
Interventions
Subcutaneous, 20 microgram (mcg)/day, 18 months